Novo’s Low-Cost Wegovy Offers Alternative To Compounders For Self-Pay Crowd

Five Doses Available At $499 Per Month

Novo is making Wegovy available through a new direct-to-patient delivery option for individuals paying out of pocket for the obesity drug as the potential end of semaglutide compounding nears.

Novo's lower-cost Wegovy options will be offered in pens while Lilly's cash-pay Zepbound products are in vials (Shutterstock)
Key Takeaways
  • Novo launched five doses of Wegovy for US cash-pay customers through NovoCare Pharmacy available at $499 per month as a lower-cost alternative for uninsured patients.

Novo Nordisk launched NovoCare Pharmacy on 5 March, through which it will sell monthly supplies of Wegovy (semaglutide) for $499...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Scrip

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit

 

Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By 

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.

More from Business

Sarepta Restructures, Cuts 500 Jobs As Elevidys-Related Deaths Impact Sales

 
• By 

After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab

 

Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.

J&J Delivers In Q2 Despite Stelara Drop, Raising Guidance

 

Stelara revenues declined 42.7% in the quarter due to biosimilars, but innovative medicines grew 4.9%, surpassing $15bn for the quarter. Although pharma tariffs could be coming, the firm said the impact continues to be hard to predict.